Business Wire

CA-WETA-DIGITAL

17.12.2020 18:17:18 CET | Business Wire | Press release

Share
Weta Digital Welcomes Distinguished Industry Leaders to Board of Directors and Establishes Offices in California

Weta Digital, one of the world’s premiere visual effects facilities and parent company of Weta Animated, has announced the addition of industry leaders Tom Staggs, Jeff Huber and Ken Kamins to its Board of Directors. The appointment of Staggs, Huber and Kamins reflect the continued growth and innovation of the company, which is also opening offices in Los Angeles and San Francisco.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201217005350/en/

“Tom, Jeff and Ken are extraordinary additions to the board of Weta Digital,” said Prem Akkaraju, Global CEO of Weta Digital. “They have established best practices at the highest levels of company management, in entertainment and digital technology. Their combined business acumen and collective depth of experience perfectly positions Weta Digital for exponential growth. Opening offices in Los Angeles and San Francisco enables storytellers to tap Weta’s production pipeline and work with concept designers, animation supervisors and other key creatives, in both the US and New Zealand. Weta Digital’s expansion comes at a time when much of the film industry is experiencing extraordinary uncertainty as we grapple with the ongoing impact of Covid-19. We’re extremely fortunate that New Zealand got in front of the curve early - it’s one of the few places in the world that has managed community transmission, where you can make a film safely, without the restrictive protocols of other markets.”

Tom Staggs brings more than 26-years of experience at The Walt Disney Company, including 18 years of C-suite experience with the company. He was most recently Disney’s Chief Operating Officer, having previously served for five years as Chairman of Disney Parks and Resorts Worldwide and for nearly 12 years as Disney’s Chief Financial Officer. During his time at Disney, Staggs helped shape Disney’s strategic, financial, operational, creative and brand management strategies across every segment of the company and helped drive many of Disney’s most important initiatives including the acquisitions of Cap Cities/ABC, Pixar and Marvel. Since departing Disney in late 2016, Staggs has focused on developing several new business ventures across a variety of fields. He is a board member and advisor to a number of private companies, and also serves on the board of directors of music streaming service Spotify. Before joining Disney, Staggs was an investment banker at Morgan Stanley and Dain Bosworth.

“I have long admired Peter Jackson and Fran Walsh’s filmmaking talents and Weta Digital’s accomplishments in animation and visual effects. Weta Digital’s rare combination of creative talent and technology gives them a unique ability to succeed in high-end animation production,” said Staggs. “I look forward to working with Peter, Fran, Prem and the entire Weta Digital team on the animation business and further global expansion.”

Jeff Huber is the former Founding CEO and Vice Chairman of GRAIL and previously a Senior Vice President at Google. Having spent over 13 years at Google, Huber co-founded the company’s life sciences efforts in Google X and led development and scaling for Google Maps, Google Apps and Google Ads. During his tenure as an executive at Google, Jeff oversaw 50x growth in revenues (from $1 billion to >$50 billion) and organization (1,000 to >50,000 employees), and managed a $5 billion P&L and large distributed teams (5,000+ direct-line employees). Prior to Google, Huber served as Vice President of Architecture and Systems Development at eBay and Senior Vice President of Engineering at Excite@Home, where he led consumer product and infrastructure development.

"Weta Digital is known around the world for its astounding visual effects and inventive storytelling. This amazing artistry is driven by groundbreaking technology and non-stop innovation,” said Huber. “The research and development teams at Weta Digital have consistently produced magic and raised the bar as to what is possible. I look forward to the adventures ahead with Peter, Fran, Prem and the entire Weta Digital Team, growing the company in scale and technology excellence to create the next generation of culture-defining stories and experiences."

Ken Kamins is the Founder and CEO of Key Creatives, a management-production company. He has represented Peter Jackson and Fran Walsh since 1992, and his Executive Producer credits include The Hobbit Trilogy , District 9 , and The Adventures of Tintin: The Secret of the Unicorn. Prior to his current position, he served as Executive Vice President of the talent agency, International Creative Management; and before that, as Executive Vice President of RCA/Columbia Pictures Home Entertainment.

“I’ve had a front row seat for the entire growth curve of Weta Digital, from its beginnings in 1993 when the company consisted of just one computer and one artist creating the digital effects in “Heavenly Creatures”, through to this moment,” said Kamins. “Weta Digital was designed by Peter and Fran to be a creative haven for filmmakers - a place where they could let their imaginations run wild. No idea was too crazy or too difficult to try. In collaboration with the many great artists Weta has had the privilege to work with, Joe Letteri, David Conley and their teams have consistently pushed the boundaries of imaginative storytelling.”

Staggs, Huber and Kamins join Weta Digital board members Peter Jackson, Fran Walsh, Sean Parker, Joe Letteri and CEO Prem Akkaraju.

ABOUT WETA DIGITAL:

Weta Digital is the standard-bearer for creativity and innovation in visual effects and animation, attracting talent, partners, and clients that seek to push what is possible in pursuit of their artistic vision. Weta’s proprietary pipeline continues to evolve and provide artists with the tools they need to create their best work. Based in Wellington, New Zealand, Weta Digital is the largest single-site VFX studio in the world drawing artists from over 40 countries. They are some of the most creative and ambitious artists, engineers, and executives in entertainment and their work has earned six visual effects Academy Awards, ten Academy Sci-Tech Awards and six visual effects BAFTA Awards in addition to the 34 Visual Effects Society Awards awarded to them by their peers. Ground-breaking, performance-driven animated characters from Gollum to Caesar, and worlds from Middle-earth to Pandora, are regarded as some of the best visual effects ever to appear on screen.

For more information:
Corporate: www.wetastudios.com
Weta Digital: www.wetafx.co.nz
Follow: @weta_digital

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release

Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release

Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release

Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release

− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release

Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye